Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
Mylan II B.V. (MYL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/23/2020 |
GN
| ROSEN, A LEADING LAW FIRM, Reminds Mylan N.V. Investors of Important Tuesday Deadline in Securities Class Action – MYL |
07/18/2020 |
GN
| ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYL |
07/01/2020 |
GN
| ROSEN, A LONGSTANDING GLOBAL INVESTOR FIRM, Announces Filing of Securities Class Action Lawsuit Against Mylan N.V. – MYL |
06/30/2020 |
GN
| MYL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Mylan N.V. Investors of Class Action and Lead Plaintiff Deadline: August 25, 2020 |
04/30/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of FGL Holdings (FG), Franklin Financial Network, Inc. (FSB), Mylan N.V. (MYL) and Willis Towers Watson Public Limited Company (WLTW) |
04/21/2020 |
GN
| OPB, TERP, MYL, and FG SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers |
01/29/2020 |
GN
| SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BZUN, FCAU, MYL, OPRA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
01/28/2020 |
GN
| FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BZUN, MAT, MYL and TCNNF |
01/27/2020 |
GN
| SHAREHOLDER ALERT: CLAIMSFILER REMINDS FSCT, MAT, MYL, TCNNF INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
01/17/2020 |
GN
| SHAREHOLDER ALERT: CLAIMSFILER REMINDS FSCT, MAT, MYL, TCNNF INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
01/14/2020 |
GN
| FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BZUN, MAT, MYL and TCNNF |
01/13/2020 |
GN
| SHAREHOLDER ALERT: CLAIMSFILER REMINDS FSCT, MATT, MYL, TCNNF INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
01/10/2020 |
GN
| SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BZUN, FSCT, MAT, MYL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
01/07/2020 |
GN
| FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BZUN, MATT and MYL |
01/06/2020 |
GN
| SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BZUN, MATT, MYL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
01/01/2020 |
GN
| SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BZUN, MYL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
01/01/2020 |
GN
| FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BZUN and MYL |
12/30/2019 |
GN
| SHAREHOLDER ALERT: CLAIMSFILER REMINDS BZUN, FCAU, MYL, REAL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
12/27/2019 |
GN
| SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BZUN, MYL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits |
12/20/2019 |
GN
| INVESTOR ALERT - Mylan N.V. (MYL) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: February 14, 2020 |
09/04/2019 |
GN
| Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019 |
07/15/2019 |
GN
| Mapi Pharma to Build a New Sterile Injectable Production Plant for GA Depot in Jerusalem |
10/09/2018 |
GN
| Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin |
06/12/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Regency Centers, Motorola Solutions, California Resources, Echelon, Mylan N.V., and Nordstrom — New Research Emphasizes Economic Growth |
02/16/2018 |
GN
| Detailed Research: Economic Perspectives on OUTFRONT Media, Mylan N.V, Axcelis Technologies, Patterson-UTI Energy, SAExploration, and vTv Therapeutics — What Drives Growth in Today's Competitive Landscape |
01/03/2018 |
GN
| Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept) |
11/01/2017 |
GN
| Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept) |
|
|